Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells
Eumelanogenesis
Small Molecule Libraries -- chemistry -- pharmacology
Repressor Proteins -- chemistry -- pharmacology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Antineoplastic Agents
Apoptosis
Drug Screening Assays
Cell Proliferation -- drug effects
Dose-Response Relationship
Small Molecule Libraries
Structure-Activity Relationship
03 medical and health sciences
Prohibitins
LC3
Tumor Cells, Cultured
Humans
Melanoma
Antineoplastic Agents -- chemistry -- pharmacology
Cancer
Cell Proliferation
MITF
0303 health sciences
Cultured
Dose-Response Relationship, Drug
Molecular Structure
Melanocytes -- drug effects
Antitumor
Sciences bio-médicales et agricoles
[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences
Melanoma -- drug therapy -- pathology
Tumor Cells
3. Good health
Repressor Proteins
ERK
Triazine
Melanocytes
Drug
Drug Screening Assays, Antitumor
Apoptosis -- drug effects
DOI:
10.1016/j.ejmech.2018.06.052
Publication Date:
2018-06-23T16:18:36Z
AUTHORS (11)
ABSTRACT
Prohibitins 1 and 2 (PHB1/2) are scaffold proteins that are involved in both melanogenesis and oncogenic pathways. We hypothesized that a PHB1 ligand, melanogenin, may display anti-cancer effects in addition to its known melanogenic activity in melanocytes. Here, we disclose a convenient synthesis of melanogenin, and its analogs. We found that, among 57 new melanogenin analogs, two (Mel9 and Mel41) significantly promoted both melanogenesis in melanocytes by activating one of the PHB2-interacting proteins, microtubule-associated protein light chain 3 (LC3), and upregulating the expression of microphthalmia associated transcription factor (MITF). These analogs also activate ERK. Besides, in addition to their promelanogenic activities, we uncovered that melanogenin and its active analogs induce apoptosis in several cancer cell lines, including melanoma cells, and that this effect is caused by an inhibition of AKT survival pathway. Our findings present a new putative function for PHBs as regulators of LC3/ERK/MITF melanogenic signaling, and suggest that Mel9 and Mel41 may provide the basis for the development of new drugs candidates to treat melanoma and other types of cancers.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (32)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....